HDAC inhibitors in HIV

Fiona Wightman, Paula Clarisa Ellenberg, Melissa Churchill, Sharon R Lewin

Research output: Contribution to journalArticleResearchpeer-review

93 Citations (Scopus)

Abstract

Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV-infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed. There is now a concerted effort from scientists, clinicians and funding agencies to identify ways to achieve either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells). Multiple strategies aiming at achieving a cure for HIV are currently being investigated, including both pharmacotherapy and gene therapy. In this review, we will review the rationale as well as in vitro and clinical trial data that support the role of histone deacetylase inhibitors as one approach to cure HIV.
Original languageEnglish
Pages (from-to)47 - 54
Number of pages8
JournalImmunology and Cell Biology
Volume90
Issue number1
DOIs
Publication statusPublished - 2012

Cite this

Wightman, F., Ellenberg, P. C., Churchill, M., & Lewin, S. R. (2012). HDAC inhibitors in HIV. Immunology and Cell Biology, 90(1), 47 - 54. https://doi.org/10.1038/icb.2011.95
Wightman, Fiona ; Ellenberg, Paula Clarisa ; Churchill, Melissa ; Lewin, Sharon R. / HDAC inhibitors in HIV. In: Immunology and Cell Biology. 2012 ; Vol. 90, No. 1. pp. 47 - 54.
@article{77e33535ff104b01bc0373339b26e0e1,
title = "HDAC inhibitors in HIV",
abstract = "Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV-infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed. There is now a concerted effort from scientists, clinicians and funding agencies to identify ways to achieve either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells). Multiple strategies aiming at achieving a cure for HIV are currently being investigated, including both pharmacotherapy and gene therapy. In this review, we will review the rationale as well as in vitro and clinical trial data that support the role of histone deacetylase inhibitors as one approach to cure HIV.",
author = "Fiona Wightman and Ellenberg, {Paula Clarisa} and Melissa Churchill and Lewin, {Sharon R}",
year = "2012",
doi = "10.1038/icb.2011.95",
language = "English",
volume = "90",
pages = "47 -- 54",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "John Wiley & Sons",
number = "1",

}

Wightman, F, Ellenberg, PC, Churchill, M & Lewin, SR 2012, 'HDAC inhibitors in HIV', Immunology and Cell Biology, vol. 90, no. 1, pp. 47 - 54. https://doi.org/10.1038/icb.2011.95

HDAC inhibitors in HIV. / Wightman, Fiona; Ellenberg, Paula Clarisa; Churchill, Melissa; Lewin, Sharon R.

In: Immunology and Cell Biology, Vol. 90, No. 1, 2012, p. 47 - 54.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - HDAC inhibitors in HIV

AU - Wightman, Fiona

AU - Ellenberg, Paula Clarisa

AU - Churchill, Melissa

AU - Lewin, Sharon R

PY - 2012

Y1 - 2012

N2 - Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV-infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed. There is now a concerted effort from scientists, clinicians and funding agencies to identify ways to achieve either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells). Multiple strategies aiming at achieving a cure for HIV are currently being investigated, including both pharmacotherapy and gene therapy. In this review, we will review the rationale as well as in vitro and clinical trial data that support the role of histone deacetylase inhibitors as one approach to cure HIV.

AB - Combination antiretroviral therapy (cART) has led to a very substantial reduction in morbidity and mortality in HIV-infected patients; however, cART alone is unable to cure HIV and therapy is lifelong. Therefore, a new strategy to cure HIV is urgently needed. There is now a concerted effort from scientists, clinicians and funding agencies to identify ways to achieve either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells). Multiple strategies aiming at achieving a cure for HIV are currently being investigated, including both pharmacotherapy and gene therapy. In this review, we will review the rationale as well as in vitro and clinical trial data that support the role of histone deacetylase inhibitors as one approach to cure HIV.

UR - http://www.nature.com/icb/journal/v90/n1/pdf/icb201195a.pdf

U2 - 10.1038/icb.2011.95

DO - 10.1038/icb.2011.95

M3 - Article

VL - 90

SP - 47

EP - 54

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 1

ER -

Wightman F, Ellenberg PC, Churchill M, Lewin SR. HDAC inhibitors in HIV. Immunology and Cell Biology. 2012;90(1):47 - 54. https://doi.org/10.1038/icb.2011.95